Company news

Novartis AG news in 2026

Novartis AG's news releases, calls and decks from 2026, newest first.

View company

Novartis AG Enterprise Technology Report 2025: Digital Transformation Strategies, Innovation Programs, Technology Initiatives, Partnerships, Investment & Acquisition, Network Map

February 25, 2026

New real‑world data reinforce earlier use of Pluvicto™ before chemotherapy in metastatic castration-resistant prostate cancer

February 24, 2026

Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)

February 23, 2026

Radioligand Therapy Market to Surge with 13.1% CAGR: Projected Growth from $2.6B in 2025 to $4.8B by 2030 - Novartis' Pluvicto and Lutathera Have Catalyzed Commercial Momentum

February 19, 2026

Unnatural Products Announces Licensing Agreement with Novartis to Develop Macrocyclic Peptide Therapeutics

February 18, 2026

Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)

February 18, 2026

Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) | DelveInsight

February 17, 2026

Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy

February 13, 2026

Niowave and Novartis Enter Global Actinium-225 Supply Agreement to Advance Next-Generation Cancer Therapies

February 11, 2026

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

February 6, 2026

Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025

February 4, 2026

NFL Greats and Novartis Tackle Prostate Cancer Myths at Super Bowl LX: "Relax, It's a Blood Test"

January 29, 2026

Davos Spotlight | EVYD, Ministry of Health Brunei Darussalam and Novartis Foundation Launch National AI-Powered Cardiovascular Disease Prevention Initiative

January 27, 2026

Argo Biopharma Announces First Patient Dosed in Phase 2b Trial of siRNA Therapeutic BW-20829 in Patients with Elevated Lp(a)

January 25, 2026

Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease

January 16, 2026

Zonsen PepLib Biotech and Novartis Sign Worldwide License Agreement regarding Radioligand Therapy Asset

January 13, 2026

SciNeuro and Novartis Enter into a Licensing and Collaboration Agreement for Next Generation Therapeutics to Treat Alzheimer's Disease

January 12, 2026

Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment

January 9, 2026

BizClik Launches January 2026 Sustainability Portfolio With Insights From Novartis and Amazon

January 8, 2026

← Newer news releases

Calls in 2026

Decks in 2026